SD BioSensor Inc., an in-vitro diagnostic company, provides point-of-care diagnostic solutions in South Korea and internationally. The company's products include STANDARD Q, which provides various rapid test parameters comprising COVID-19 products and other parameters; STANDARD F, a multi-parametric and random accessible FIA system that provides diagnostic results to the laboratories; and STANDARD E, an enzyme linked immunosorbent assay for mass screening tests. Its products also include STANDARD M, a point-of-care MDx system for clinical decision making near-the-patient, which include analyzers, assay menus, qPCR reagents, and NA extraction kits; procell Dx, an in vitro diagnostic products for the diagnosis of infectious disease, such as tuberculosis and SARS-CoV-2, and for checking the immune status of individuals through the interferon gamma release assay; and blood glucose meters. The company was founded in 2010 and is headquartered in Suwon, South Korea.
Revenue of SD BioSensor, Inc (137310.KS)
Revenue in 2023 (TTM): $467.35 M
According to SD BioSensor, Inc's latest financial reports the company's current revenue (TTM) is $467.35 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of SD BioSensor, Inc
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $467.35 M | $20.82 M | $-178,803,810 | $-312,630,046 | $-333,369,859 |
| 2022 | $2.09 B | $992.88 M | $846.37 M | $885.32 M | $649.59 M |
| 2021 | $2.09 B | $1.12 B | $1 B | $1.03 B | $775.83 M |
| 2020 | $1.2 B | $611.67 M | $531.9 M | $511.22 M | $438.81 M |
| 2019 | $52.01 M | $14.83 M | $4.17 M | $1.57 M | $2.25 M |
| 2018 | $46.78 M | $14.28 M | $6.03 M | $2.72 M | $2.16 M |